This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Yoshida, M.
Right arrow Articles by Shikanai-Yasuda, M. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshida, M.
Right arrow Articles by Shikanai-Yasuda, M. A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, November 2009, p. 1583-1586, Vol. 16, No. 11
1071-412X/09/$08.00+0     doi:10.1128/CVI.00265-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Increased Immunoglobulin G Anti-Paracoccidioides brasiliensis Serum Antibody Avidity as a Predictor of Favorable Posttherapeutic Evolution in Paracoccidioidomycosis{triangledown}

Márcia Yoshida,1* Maria Carmen Arroyo Sanchez,2 and Maria Aparecida Shikanai-Yasuda1

Departamento de Moléstias Infecciosas e Parasitárias, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo e Laboratório de Investigação Médica-LIM 48, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo,1 Laboratório de Soroepidemiologia e Imunobiologia, Instituto de Medicina Tropical de São Paulo, São Paulo, Brazil2

Received 9 June 2009/ Returned for modification 3 August 2009/ Accepted 26 August 2009

Paracoccidioidomycosis is endemic in Latin America, and ca. 80% of all cases occur in Brazil. Little is known about antibody avidity or the evolution of such avidity in the posttherapeutic period for the different clinical presentations of the disease. In the present study, we evaluated 53 patients with paracoccidioidomycosis and calculated the avidity index. Medium- and high-avidity antibodies were found in 79.5% of patients with chronic presentation (n = 39). Among patients with the acute form (n = 14), 57.1% of the antibodies presented low avidity. In the posttherapeutic period, there was a significant increase in antibody avidity in patients presenting with the chronic multifocal form. In our preliminary study, which needs to be confirmed using a larger number of samples, the optimized method for studying antibody avidity detected differences among the clinical presentations of the mycosis and indicated the value of the avidity index as a marker of posttherapeutic evolution of patients with a multifocal chronic form of the disease.

* Corresponding author. Mailing address: Departamento de Moléstias Infecciosas e Parasitárias, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo e Laboratório de Investigação Médica-LIM 48, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. Phone: 55 11 30617047. Fax: 55 11 30618270. E-mail: marciayoshida{at}yahoo.com.br

{triangledown} Published ahead of print on 2 September 2009.

Clinical and Vaccine Immunology, November 2009, p. 1583-1586, Vol. 16, No. 11
1071-412X/09/$08.00+0     doi:10.1128/CVI.00265-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»